CN1688581A - [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂 - Google Patents

[1,2,4]－三唑二环腺苷A2ａ受体拮抗剂 Download PDF

Info

Publication number
CN1688581A
CN1688581A CNA028239679A CN02823967A CN1688581A CN 1688581 A CN1688581 A CN 1688581A CN A028239679 A CNA028239679 A CN A028239679A CN 02823967 A CN02823967 A CN 02823967A CN 1688581 A CN1688581 A CN 1688581A
Authority
CN
China
Prior art keywords
alkyl
compound
alkoxyl group
mmol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028239679A
Other languages
English (en)
Chinese (zh)
Inventor
B·R·纽斯塔德特
H·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1688581A publication Critical patent/CN1688581A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA028239679A 2001-11-30 2002-11-26 [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂 Pending CN1688581A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
US60/334,385 2001-11-30

Publications (1)

Publication Number Publication Date
CN1688581A true CN1688581A (zh) 2005-10-26

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028239679A Pending CN1688581A (zh) 2001-11-30 2002-11-26 [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂

Country Status (18)

Country Link
US (2) US6875772B2 (https=)
EP (1) EP1453836B1 (https=)
JP (2) JP4429724B2 (https=)
KR (1) KR20050044600A (https=)
CN (1) CN1688581A (https=)
AR (1) AR037681A1 (https=)
AT (1) ATE358130T1 (https=)
AU (1) AU2002352933A1 (https=)
CA (1) CA2468658C (https=)
DE (1) DE60219196T2 (https=)
ES (1) ES2283625T3 (https=)
HU (1) HUP0402324A3 (https=)
IL (1) IL161573A0 (https=)
MX (1) MXPA04005158A (https=)
PE (1) PE20030653A1 (https=)
TW (1) TW200300689A (https=)
WO (1) WO2003048163A1 (https=)
ZA (1) ZA200404168B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
CN117120443A (zh) * 2021-04-23 2023-11-24 株式会社 钟根堂 作为腺苷A2a受体拮抗剂的化合物及包含其的药物组合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161573A0 (en) * 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
BR0308347A (pt) * 2002-03-12 2005-01-25 Wyeth Corp Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais
WO2004029056A1 (ja) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
US20090124663A1 (en) * 2005-06-08 2009-05-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200803856A (en) 2005-09-02 2008-01-16 Mount Cook Biosciences Inc Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
KR102633145B1 (ko) * 2018-06-26 2024-02-05 쩌지앙 빔그린 파머슈티컬스, 엘티디 A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
JP2023508182A (ja) * 2019-12-26 2023-03-01 チェジン ヴィムグリーン ファーマシューティカルズ リミテッド トリアゾロトリアジン誘導体の疾患治療への応用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) * 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
DE69820866T2 (de) * 1997-03-24 2004-12-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) * 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
WO2000017201A1 (en) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
KR100687954B1 (ko) * 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
IL161573A0 (en) * 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
CN117120443A (zh) * 2021-04-23 2023-11-24 株式会社 钟根堂 作为腺苷A2a受体拮抗剂的化合物及包含其的药物组合物
TWI838736B (zh) * 2021-04-23 2024-04-11 韓商鐘根堂股份有限公司 做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物

Also Published As

Publication number Publication date
JP4429724B2 (ja) 2010-03-10
US20030191130A1 (en) 2003-10-09
KR20050044600A (ko) 2005-05-12
ES2283625T3 (es) 2007-11-01
JP2005511697A (ja) 2005-04-28
TW200300689A (en) 2003-06-16
AU2002352933A1 (en) 2003-06-17
CA2468658C (en) 2009-04-14
HK1064097A1 (en) 2005-01-21
DE60219196D1 (de) 2007-05-10
EP1453836B1 (en) 2007-03-28
MXPA04005158A (es) 2004-08-11
HUP0402324A2 (hu) 2005-02-28
PE20030653A1 (es) 2003-08-04
US7078408B2 (en) 2006-07-18
WO2003048163A1 (en) 2003-06-12
ATE358130T1 (de) 2007-04-15
IL161573A0 (en) 2004-09-27
JP2010018634A (ja) 2010-01-28
HUP0402324A3 (en) 2008-09-29
AR037681A1 (es) 2004-12-01
US6875772B2 (en) 2005-04-05
EP1453836A1 (en) 2004-09-08
US20050113380A1 (en) 2005-05-26
ZA200404168B (en) 2005-09-02
CA2468658A1 (en) 2003-06-12
DE60219196T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1688581A (zh) [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂
CN1261433C (zh) 用作神经激肽受体拮抗剂的1,3,8－三氮杂－螺[4.5]癸－4－酮衍生物
CN1034175C (zh) 吡唑并嘧啶类化合物
CN1596258A (zh) 腺A2α受体拮抗剂
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
HK1040712A1 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
CN1288464A (zh) 作为orl－1受体激动剂的4－(2－酮－1－苯并咪唑啉基)哌啶化合物
CN1745077A (zh) 促旋酶抑制剂及其用途
CN1901917A (zh) 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3－氧代－3，4－二氢－喹喔啉－2－基－氨基)－苯甲酰胺衍生物和相关化合物
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1827603A (zh) 作用于大麻受体的新型吡唑类似物
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
HK1041483A1 (en) Bicyclic nitrogen heterocycles
CN1551881A (zh) 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1777609A (zh) 2－炔基－及2－链烯基－吡唑并－[4,3,－e]－1,2,4－三唑并[1,5－c]－嘧啶腺苷A2a受体拮抗剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1894240A (zh) 阿片受体拮抗剂
CN101076333A (zh) 可用于治疗TNF－α和IL－1介导的疾病的吡唑并杂芳基化合物
CN1221551C (zh) 作为腺苷受体配体的氨基三唑并吡啶衍生物
CN1856470A (zh) 喹啉钾通道抑制剂
CN1662522A (zh) 新颖的化合物、它们的用途和制备

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20051026